
VasoLux MicroSystems offers a novel diagnostic imaging system for precise osteoarthritis detection, aiding in effective treatment planning.
VasoLux MicroSystems, LLC (www.vasolux.com) has developed a novel diagnostic imaging system to help surgeons identify later-stage osteoarthritis patients who are best suited for cartilage repair procedures or joint replacement surgery. Osteoarthritis – a condition caused by the degradation of cartilage – is considered one of the leading causes of chronic disability worldwide and affects more than 20 million people in the U.S. alone. VasoLux’s technology quantitatively assesses the quality of cartilage, in vivo, in a non-destructive, minimally invasive procedure.
Competing procedures and technologies, such as arthroscopy, MRI, CT, Ultrasound, OCT, and X-ray cannot provide physicians with an objective measurement capable of identifying the early progression of osteoarthritis, determining the true extent of a cartilage defect, or evaluating the quality of regenerated cartilage. Consequently, physicians lack the information needed to select the appropriate therapeutic intervention or revise their treatment plan if prior efforts have not reinvigorated the cartilage or prevented its degeneration. VasoLux’s diagnostic imaging system eliminates the subjective diagnoses of osteoarthritis, which in turn reduces inefficiencies in the health care system.
Companies similar to Vasolux Microsystems include VisionScope Technologies, VasSol, Vasoptic Medical and VascuLogic.
Vasolux Microsystems was founded in 2005.
Vasolux Microsystems' headquarters is located in Elyria, OH, US.
Vasolux Microsystems' most recent funding round was for $380k (USD) in July 2009.
As of Jul 28, 2009, Vasolux Microsystems has raised a total of $380k (USD).
Vasolux Microsystems has 5 employees as of Feb 4, 2024.
Vasoptic Medical